[Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders].
D V Kurkin, E I Morkovin, D A Bakulin, Yu V Gorbunova, O V Ivanova, E V Pavlova, V I Zvereva, M A Dzhavakhyan, I S Krysanov, Yu A Kolosov, A V Zaborovsky, A V Strygin, V I Petrov, P A Beliy, K Y Zaslavskaya, D V Maltsev, M O Skripka
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova January 1, 2024 DOI: 10.17116/jnevro202412405122 via PubMed
Summary
AI-generated from the abstractDepression is a major cause of disability globally, but current drugs based on the monoamine theory have limited effectiveness. Exploring alternative mechanisms, such as targeting glutamatergic pathways in the central nervous system through modulation of NMDA and AMPA receptors, shows promising results. This review presents existing drugs with glutamatergic activity and new developments aimed at improving pharmacotherapy for depressive disorders.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Ketamine Serotonin |
| Keywords | Ampa Nmda #neuroscience |
| Key finding | Targeting glutamatergic pathways, particularly through modulation of NMDA and AMPA receptors, shows promise for enhancing the efficacy of pharmacotherapy for depressive disorders. |
Abstract
Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.